Percheron Therapeutics LimitedASX: PER

Topline Six-Month Results From Phase IIb Study of Avicursen

Dec 18, 2024 at 3:46 AM UTC · Issued by Percheron Therapeutics Limited

Percheron Therapeutics Limited has released a press release.

View Attachment